Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Revenue: 2020-2024

Historic Revenue for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to $45.6 million.

  • NewAmsterdam Pharma Co N.V's Revenue fell 98.80% to $348,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.2 million, marking a year-over-year increase of 4.91%. This contributed to the annual value of $45.6 million for FY2024, which is 223.37% up from last year.
  • According to the latest figures from FY2024, NewAmsterdam Pharma Co N.V's Revenue is $45.6 million, which was up 223.37% from $14.1 million recorded in FY2023.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's Revenue peaked at $102.7 million during FY2022, and registered a low of -$411,000 during FY2021.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's median Revenue value was $45.6 million (recorded in 2024), while the average stood at $54.1 million.
  • Per our database at Business Quant, NewAmsterdam Pharma Co N.V's Revenue surged by 25,086.37% in 2022 and then tumbled by 86.28% in 2023.
  • Yearly analysis of 5 years shows NewAmsterdam Pharma Co N.V's Revenue stood at -$392,770 in 2020, then declined by 4.64% to -$411,000 in 2021, then surged by 25,086.37% to $102.7 million in 2022, then crashed by 86.28% to $14.1 million in 2023, then spiked by 223.37% to $45.6 million in 2024.